The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer

被引：8

作者：

Nakamura, Masato ^{[1
]}

Yamada, Yasuhide ^{[2
]}

Muro, Kei ^{[3
]}

Takahashi, Keiichi ^{[4
]}

Baba, Hideo ^{[5
]}

Sasaki, Yasutsuna ^{[6
]}

Komatsu, Yoshito ^{[7
]}

Satoh, Taroh ^{[8
]}

Mishima, Hideyuki ^{[9
]}

Watanabe, Masahiko ^{[10
]}

Sakata, Yuh ^{[11
]}

Morita, Satoshi ^{[12
]}

Shimada, Yasuhiro ^{[13
]}

Sugihara, Kenichi ^{[14
]}

机构：

[1] Aizawa Hosp, Matsumoto, Nagano 3908510, Japan

[2] Natl Canc Ctr, Chuo Ku, Tokyo 1040045, Japan

[3] Aichi Canc Ctr Hosp, Chikusa Ku, Nagoya, Aichi 4648681, Japan

[4] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Bunkyo Ku, Tokyo 1138677, Japan

[5] Kumamoto Univ, Chuo Ku, Kumamoto, Kumamoto 8608556, Japan

[6] Showa Univ, Shinagawa Ku, Tokyo 1428666, Japan

[7] Hokkaido Univ Hosp, Kita Ku, Sapporo, Hokkaido 0608648, Japan

[8] Osaka Univ, Suita, Osaka 5650871, Japan

[9] Aichi Med Univ, Nagakute, Aichi 4801195, Japan

[10] Kitasato Univ, Sch Med, Minami Ku, Sagamihara, Kanagawa 2520375, Japan

[11] Misawa City Hosp, Misawa, Aomori 0330022, Japan

[12] Kyoto Univ, Sakyo Ku, Kawara, Kyoto 6068507, Japan

[13] Kochi Hlth Sci Ctr, Kochi, Kochi 7818555, Japan

[14] Tokyo Med & Dent Univ, Grad Sch, Bunkyo Ku, Tokyo 1138510, Japan

来源：

FUTURE ONCOLOGY | 2015年 / 11卷 / 10期

关键词：

DPD inhibitory fluoropyrimidine; metastatic colorectal cancer; oxaliplatin; S-1; SOFT trial; SOX; COST-EFFECTIVENESS ANALYSIS; ANTITUMOR-ACTIVITY; NON-INFERIORITY; COLON-CANCER; OPEN-LABEL; ORAL S-1; XELOX; 5-FLUOROURACIL; FLUOROURACIL; THERAPY;

D O I：

10.2217/fon.15.59

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

A combination of oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) plus bevacizumab has been widely used for the first-line chemotherapy of metastatic colorectal cancer (mCRC). S-1 is an oral fluoropyrimidine preparation that combines tegafur, a prodrug of 5-fluorouracil, with two modulators. Several studies of combination chemotherapy with oxaliplatin plus S-1 (SOX) conducted in Asia have reported promising efficacy and safety in patients with mCRC, suggesting the potential to replace mFOLFOX6. The SOFT trial (JapicCTI-090699) was a randomized Phase III trial designed to evaluate the noninferiority of SOX plus bevacizumab to mFOLFOX6 plus bevacizumab in patients with mCRC. This review summarizes the drug concept of S-1 and the results of clinical trials of S-1 and SOX in CRC and presents an overview of the SOFT trial.

引用

页码：1471 / 1478

页数：8

共 44 条

[1]

Aitini Enrico, 2012, Cancer Manag Res, V4, P99, DOI 10.2147/CMAR.S29267

[2]

XELOX (capecitabine plus oxaliplatin):: Active first-line therapy for patients with metastatic colorectal cancer [J].

Cassidy, J ;

Tabernero, J ;

Twelves, C ;

Brunet, R ;

Butts, C ;

Conroy, T ;

Debraud, F ;

Figer, A ;

Grossmann, J ;

Sawada, N ;

Schöffski, P ;

Sobrero, A ;

Van Cutsem, E ;

Diaz-Rubio, E .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2084-2091

[3]

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer [J].

Cassidy, Jim ;

Clarke, Stephen ;

Diaz-Rubio, Eduardo ;

Scheithauer, Werner ;

Figer, Arie ;

Wong, Ralph ;

Koski, Sheryl ;

Lichinitser, Mikhail ;

Yang, Tsai-Shen ;

Rivera, Fernando ;

Couture, Felix ;

Sirzen, Florin ;

Saltz, Leonard .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) :2006-2012

[4]

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].

de Gramont, A ;

Figer, A ;

Seymour, M ;

Homerin, M ;

Hmissi, A ;

Cassidy, J ;

Boni, C ;

Cortes-Funes, H ;

Cervantes, A ;

Freyer, G ;

Papamichael, D ;

Le Bail, N ;

Louvet, C ;

Hendler, D ;

de Braud, F ;

Wilson, C ;

Morvan, F ;

Bonetti, A .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947

[5]

S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study [J].

Furuse, Junji ;

Okusaka, Takuji ;

Boku, Narikazu ;

Ohkawa, Shinichi ;

Sawaki, Akira ;

Masumoto, Toshikazu ;

Funakoshi, Akihiro .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (05) :849-855

[6]

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial [J].

Heinemann, Volker ;

von Weikersthal, Ludwig Fischer ;

Decker, Thomas ;

Kiani, Alexander ;

Vehling-Kaiser, Ursula ;

Al-Batran, Salah-Eddin ;

Heintges, Tobias ;

Lerchenmueller, Christian ;

Kahl, Christoph ;

Seipelt, Gernot ;

Kullmann, Frank ;

Stauch, Martina ;

Scheithauer, Werner ;

Hielscher, Joerg ;

Scholz, Michael ;

Mueller, Sebastian ;

Link, Hartmut ;

Niederle, Norbert ;

Rost, Andreas ;

Hoeffkes, Heinz-Gert ;

Moehler, Markus ;

Lindig, Reinhard U. ;

Modest, Dominik P. ;

Rossius, Lisa ;

Kirchner, Thomas ;

Jung, Andreas ;

Stintzing, Sebastian .

LANCET ONCOLOGY, 2014, 15 (10) :1065-1075

[7]

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial [J].

Hong, Yong Sang ;

Park, Young Suk ;

Lim, Ho Yeong ;

Lee, Jeeyun ;

Kim, Tae Won ;

Kim, Kyu-pyo ;

Kim, Sun Young ;

Baek, Ji Yeon ;

Kim, Jee Hyun ;

Lee, Keun-Wook ;

Chung, Ik-Joo ;

Cho, Sang-Hee ;

Lee, Kyung Hee ;

Shin, Sang Joon ;

Kang, Hye Jin ;

Shin, Dong Bok ;

Jo, Sook Jung ;

Lee, Jae Won .

LANCET ONCOLOGY, 2012, 13 (11) :1125-1132

[8]

Inuyama Y, 2001, Gan To Kagaku Ryoho, V28, P1381

[9]

Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer [J].

Kawahara, M ;

Furuse, K ;

Segawa, Y ;

Yoshimori, K ;

Matsui, K ;

Kudoh, S ;

Hasegawa, K ;

Niitani, H .

BRITISH JOURNAL OF CANCER, 2001, 85 (07) :939-943

[10]

KIMURA K, 1980, Gastroenterologia Japonica, V15, P324

← 1 2 3 4 5 →